Path Fertility secures $2 million NIH grant to develop and validate a semen-based epigenetic assay for NOA and cancer risk.

Agendia presented data on an AI pathology model that predicts breast cancer recurrence risk from routine biopsy slides.

Abbott launches its Oncodetect MRD test, using WGS to track up to 5,000 variants and improve cancer recurrence detection sensitivity.

Tempus xR RNA sequencing assay receives EU IVDR Class C certification, supporting continued clinical and biopharma access in ...

Medicare now reimburses Lucid Diagnostics’ EsoGuard esophageal DNA test at $1,938 per test, following its $15 million private placement.

Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its breast cancer genomic testing portfolio, the ...

Abbott’s WGS-based Oncodetect MRD test showed a 30% sensitivity improvement for post-surgical colorectal cancer recurrence.

The acquisition adds a saliva assay for periodontal pathogen detection, extending the CLIA-certified laboratory’s services to dental practices. Real Diagnostics, a CLIA-certified clinical laboratory ...

FDA grants bioMérieux dual clearance and CLIA waiver for the BIOFIRE SPOTFIRE Vaginitis Panel, a rapid 20-minute ...

Biodesix, in partnership with Bio-Rad and Thermo Fisher Scientific, advances tumor-informed and tumor-naïve MRD assays for ...

Hologic and Inpeco have partnered to connect Panther Systems with FlexLab X automation in Europe, aiming to improve ...

A study finds permissive lab screening thresholds double primary aldosteronism detection rates versus Endocrine Society ...